The UK Technology Strategy Board has announced two new funding competitions as part of its £21.5 million Regenerative Medicine Programme. Under the heading of Regenerative Medicine Programme: Tools and Technologies, the Technology Strategy Board, Medical Research Council, Biotechnology and Biological Sciences Research Council and Engineering and Physical Sciences Research Council will invest up to £8 million in collaborative R&D projects. The intention is to establish consortia that address generic challenges in the development of cell-based therapies and will lead to demonstrators with commercial applicability, says the organisation. Applications must be industrially led and are expected to consist of academic, industrial and end-user collaborators.
Through the Regenerative Medicine Programme: Developing Therapeutics 2 competition, the Technology Strategy Board will invest up to £2.5 million in commercial R&D projects in the area of regenerative medicine therapeutics. The aim is to support businesses in the preclinical, and particularly clinical, development of regenerative medicine therapeutics. Projects must be collaborative and led by a business.
Consortium-building workshops will take place on 17 February (Leeds), 21 February (Edinburgh) and 28 February (London).
The two-stage competitions open on 14 March 2011 and compulsory expressions of interest must be submitted by 20 April 2011. The deadline for receipt of full applications is 20 July 2011.